Program 2 -Endocrinology includes basic, translational, and clinical studies with a common theme of evaluating hormonal and growth factor regulation of cell growth and function. Major investigative efforts are focused in the areas of steroid hormone action and steroid-dependent cancers, and on how growth hormones and cytokines act to promote cell growth, tumor development and metastasis through direct, paracrine, autocrine, or novel mechanisms. The overall scientific goals of the Program are to understand how these processes are regulated in normal cells and tissues, how dysregulation of hormonally-regulated pathways result in aberrant growth of cancer cells and metastasis, and how to prevent or treat such cancers. To achieve these goals, investigators conduct studies on: Hormone regulatory processes in normal and cancer cells; Potential therapeutic targets for prevention of or treatment of cancer; and Collaborative studies on patient treatment and survival. The Program has 21 investigators from 9 clinical and basic science departments in the School of Medicine and College of Arts and Sciences, representing a wide variety of intellectual, technical and clinical expertise. Program investigators interact through dedicated Program meetings, seminar series such as those sponsored by the Cancer Center and Endocrinology, and the Endocrinology Cancer Center Program retreat. Program members also collaborate with other investigators in program projects and working groups for prostate and breast cancer, and women's oncology. These collaborations have been highly successful, as shown by joint grants and publications. For example, of 333 total Program publications, 24% have intra-programmatic, and 28% have inter-programmatic authors. These joint efforts include work on mechanisms of cross-talk between steroids and growth factors in cancer, identification of common signaling molecules for steroids and growth factors in cell proliferation, and mechanisms by which steroid hormone-dependent cancers become hormone-independent. Membership requires that an investigator have an established cancer-focused or cancer-relevant program on endocrine regulation of cell growth and function. The cancer focus has increased substantially since the last renewal, with NCI funding increasing 3-fold ($1.2M in 2005) and cancer-directed funding from the DOD increasing 2- fold. In the past year, Program faculty received over $7 million in peer-reviewed support and over $8.7 million dollars in total direct cost (peer-reviewed and non peer-reviewed).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA044579-17
Application #
7726741
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2007-02-01
Budget End
2008-01-31
Support Year
17
Fiscal Year
2007
Total Cost
$17,008
Indirect Cost
Name
University of Virginia
Department
Type
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Kulling, Paige M; Olson, Kristine C; Hamele, Cait E et al. (2018) Dysregulation of the IFN-?-STAT1 signaling pathway in a cell line model of large granular lymphocyte leukemia. PLoS One 13:e0193429
Grant, Margaret J; Loftus, Matthew S; Stoja, Aiola P et al. (2018) Superresolution microscopy reveals structural mechanisms driving the nanoarchitecture of a viral chromatin tether. Proc Natl Acad Sci U S A 115:4992-4997
Knapp, Kiley A; Pires, Eusebio S; Adair, Sara J et al. (2018) Evaluation of SAS1B as a target for antibody-drug conjugate therapy in the treatment of pancreatic cancer. Oncotarget 9:8972-8984
Kedzierska, Katarzyna Z; Gerber, Livia; Cagnazzi, Daniele et al. (2018) SONiCS: PCR stutter noise correction in genome-scale microsatellites. Bioinformatics 34:4115-4117
Zhang, Xuewei; Kitatani, Kazuyuki; Toyoshima, Masafumi et al. (2018) Ceramide Nanoliposomes as a MLKL-Dependent, Necroptosis-Inducing, Chemotherapeutic Reagent in Ovarian Cancer. Mol Cancer Ther 17:50-59
Cruickshanks, Nichola; Zhang, Ying; Hine, Sarah et al. (2018) Discovery and Therapeutic Exploitation of Mechanisms of Resistance to MET Inhibitors in Glioblastoma. Clin Cancer Res :
Balogh, Kristen N; Templeton, Dennis J; Cross, Janet V (2018) Macrophage Migration Inhibitory Factor protects cancer cells from immunogenic cell death and impairs anti-tumor immune responses. PLoS One 13:e0197702
Gonzalez, Phillippe P; Kim, Jungeun; Galvao, Rui Pedro et al. (2018) p53 and NF 1 loss plays distinct but complementary roles in glioma initiation and progression. Glia 66:999-1015
Rodriguez, Anthony B; Peske, J David; Engelhard, Victor H (2018) Identification and Characterization of Tertiary Lymphoid Structures in Murine Melanoma. Methods Mol Biol 1845:241-257
Stowman, Anne M; Hickman, Alexandra W; Mauldin, Ileana S et al. (2018) Lymphoid aggregates in desmoplastic melanoma have features of tertiary lymphoid structures. Melanoma Res 28:237-245

Showing the most recent 10 out of 539 publications